Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERCC1 | P07992 | 1/20 | 0.51 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.51 |
| ▸ | IDO1 | P14902 | 6/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.42 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.42 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5615559 | 0.98 | ERCC1 (0.50) | ERCC1ERCC4IDO1CYP1A2CYP3A4 | |
| SCHEMBL13321612 | 0.84 | CYP3A4 (0.41) | ERCC1ERCC4IDO1CYP3A4CYP2C9 | |
| SCHEMBL1625791 | 0.83 | IDO1 (0.54) | ERCC1ERCC4IDO1CYP1A2CYP3A4 | |
| SCHEMBL27474700 | 0.82 | FLT1 (0.40) | ERCC1ERCC4IDO1CYP3A4CYP2C9 | |
| SCHEMBL27858505 | 0.82 | FLT1 (0.40) | ERCC1ERCC4IDO1CYP3A4CYP2C9 | |
| SCHEMBL27476142 | 0.82 | FLT1 (0.40) | ERCC1ERCC4IDO1CYP3A4CYP2C9 | |
| SCHEMBL27536511 | 0.82 | FLT1 (0.40) | ERCC1ERCC4IDO1CYP3A4CYP2C9 | |
| SCHEMBL271766 | 0.82 | IDO1 (0.52) | ERCC1ERCC4IDO1CYP1A2CYP3A4 | |
| SCHEMBL23706649 | 0.81 | PSEN1 (0.42) | ERCC1ERCC4CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL9488131 | 0.81 | ALDH1A1 (0.42) | CYP1A2CYP3A4CYP2C19CYP2D6ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108367529-A | Light flame-retardant thermoplastic structure | 施内勒公司 | 2018-08-03 | — | — | CN | claimed |
| EP-0449975-B1 | NON-TIN-BASED, LOW TOXICITY ANTI-FOULING AGENTS | BATTELLE MEMORIAL INSTITUTE (US) | 1997-04-23 | — | — | EP | claimed |
| CN-108367529-A | Light flame-retardant thermoplastic structure | 施内勒公司 | 2018-08-03 | — | — | CN | disclosed |
| CN-105461928-A | Linear polyarylene sulfide with active reaction side group/ionic reaction side group, and preparation method thereof | UNIV SICHUAN | 2016-04-06 | — | — | CN | disclosed |
| CN-102585474-B | Glass fiber reinforced polycarbonate resin composition with excellent flame retardancy | CHEIL IND INC | 2014-06-04 | — | — | CN | disclosed |
| CN-102780019-A | Polymer electrolyte membrane, membrane-electrode assembly and fuel battery cell each using the polymer electrolyte membrane | SUMITOMO CHEMICAL CO | 2012-11-14 | — | — | CN | disclosed |
| CN-102742051-A | Binder particles for electrochemical devices | ZEON CORP | 2012-10-17 | — | — | CN | disclosed |
| CN-102105506-A | Polymer, polyarylene block copolymer, polyelectrolyte, polyelectrolyte membrane, and fuel cell | SUMITOMO CHEMICAL CO | 2011-06-22 | — | — | CN | disclosed |
| EP-1223923-B1 | UNSATURATED ARYL SULFONES FOR PROTECTING NORMAL CELLS FROM CYTOTOXICITY OF CHEMOTHERAPEUTIC AGENTS | UNIV TEMPLE (US) | 2010-03-31 | — | — | EP | disclosed |
| US-7595347-B2 | Method for protecting normal cells from cytotoxicity of chemotherapeutic agents | Temple University—Of the Commonwealth System of Higher Education (US) | 2009-09-29 | — | — | US | disclosed |
| CN-101517797-A | Polymer electrolyte membrane, method for producing the same, membrane-electrode assembly and fuel cell using the same, and method for evaluating ion conductivity of polymer electrolyte membrane | SUMITOMO CHEMICAL CO (JP) | 2009-08-26 | — | — | CN | disclosed |
| US-6656973-B2 | Anticancer chemotherapy, and cytoprotective agents administered before, during or after chemotherapy to protect the normal cells of the patient | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2003-12-02 | — | — | US | disclosed |
| US-20030216535-A1 | (E)-styryl sulfone anticancer agents | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2003-11-20 | — | — | US | disclosed |
| US-20030149109-A1 | (E)-4-carboxystyrl-4-chlorobenzyl sulfone and pharmaceutical compositions thereof | COSENZA STEPHEN C (US) | 2003-08-07 | — | — | US | disclosed |
| EP-1173160-A4 | (E)-STYRYL SULFONE ANTICANCER AGENTS | UNIV TEMPLE (US) | 2003-02-19 | — | — | EP | disclosed |
| EP-1223923-A1 | METHOD FOR PROTECTING NORMAL CELLS FROM CYTOTOXICITY OF CHEMOTHERAPEUTIC AGENTS | Temple University of the Commonwealth System of Higher Education (US) | 2002-07-24 | — | — | EP | disclosed |
| EP-1173160-A1 | (E)-STYRYL SULFONE ANTICANCER AGENTS | Temple University of the Commonwealth System of Higher Education (US) | 2002-01-23 | — | — | EP | disclosed |
| WO-2001026645-A1 | METHOD FOR PROTECTING NORMAL CELLS FROM CYTOTOXICITY OF CHEMOTHERAPEUTIC AGENTS | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2001-04-19 | — | — | WO | disclosed |
| WO-2000059495-A1 | (E)-STYRYL SULFONE ANTICANCER AGENTS | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2000-10-12 | — | — | WO | disclosed |
| US-4007155-A | SULFONATE | GENERAL ELECTRIC COMPANY (US) | 1977-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216535-A1 | (E)-styryl sulfone anticancer agents | KRAS, CCNE1, MCL1 | ERCC1 521/4885ERCC4 902/4885IDO1 3220/4885 |
| US-20030149109-A1 | (E)-4-carboxystyrl-4-chlorobenzyl sulfone and pharmaceutical compositions thereof | CCNE1, CCNE2, TOP2B | ERCC1 117/4885ERCC4 118/4885IDO1 3323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.